A look at two of the next weight loss drugs in development, Lilly's retatrutide and Novo Nordisk's CagriSema. Details are thin, so tap through for the full piece.
Recap by typeshit. Full story at BusinessWorld Online.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
2:06:48
A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
Horek, diagnosed with the rare eye condition NAION, blames the drug and is warning others. His account is his own claim.
A personal piece from Wine Enthusiast on how taking Ozempic shifted one writer's experience of tasting wine.
Loading…